EODData

MEMBERSHIP REGISTER LOG IN

FRA, 3NK: ALPHAMAB ONCOLO.DL-000002

19 Jun 2026
LAST:

0.7900

CHANGE:
 0.03		OPEN:
0.7900		HIGH:
0.7900		ASK:
0.0000		VOLUME:
0
CHG(%):
3.27		PREV:
0.7650		LOW:
0.7900		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
19 Jun 260.79000.79000.79000.79000
18 Jun 260.76500.76500.76500.76500
17 Jun 260.75500.75500.75500.75500
16 Jun 260.74500.74500.74500.74500
15 Jun 260.76000.76000.76000.76000
12 Jun 260.77000.77000.77000.77000
11 Jun 260.77500.77500.77500.77500
10 Jun 260.70500.70500.70500.70500
09 Jun 260.69500.69500.69500.69500
08 Jun 260.72000.72000.72000.72000

PROFILE

Name:ALPHAMAB ONCOLO.DL-000002
About:Alphamab Oncology, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for cancer treatment in the People's Republic of China. The company offers KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENWEIDA brand. Its product pipeline includes KN026, an anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antibody (BsAb) that is in Phase III clinical trials to treat HER2-positive breast cancer and HER2-positive gastric cancer or gastroesophageal junction cancer; KN046, a BsAb immune checkpoint inhibitor in Phase III clinical trial for the treatment of non-small cell lung cancer (NSCLC), squamous NSCLC, triple-negative breast cancer, and recurrent and metastatic esophageal squamous cell carcinoma; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC) that is in Phase III clinical trial to treat HER2-expressing advanced or metastatic solid tumors, HER2-low expression breast cancer, platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer. In addition, the company is developing JSKN016, a bispecific ADC that is in Phase II clinical trial for the treatment of advanced malignant solid tumors, lung cancer, and breast cancer; KN019, an immunosuppressive agent in Phase II clinical trial for prophylaxis of organ rejection in adult patients receiving a kidney transplant; and JSKN033, a subcutaneous ADC in Phase I clinical trial to treat HER2-expressing advanced or metastatic solid tumors. The company also develops pre-clinical stage products for oncology comprising JSKN022, JSKN027, JSKN021, JSKN020, and JSKN028 for oncology applications. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Sector:Healthcare
Industry:Biotechnology
Address:No. 175 Fangzhou Road, Suzhou, China, 215127
Website:https://www.alphamabonc.com
ISIN:KYG0330A1013

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:40.67 
Price to Sales:1.54 
Price to Book:5.24 
Profit Margin:0.30 
Operating Margin:0.00 
Return on Assets:0.05 
Return on Equity:0.13 
Revenue:95.3M 
EBITDA:30.71M 
Shares:971.2M 
Market Cap:767.24M 

TECHNICAL INDICATORS

MA5:0.763.5%
MA10:0.755.6%
MA20:0.834.9%
MA50:0.9925.5%
MA100:0.9621.8%
MA200:1.0938.1%
STO9:100.00 
STO14:52.78
RSI14:37.31 
WPR14:-47.22
MTM14:-0.09
ROC14:-0.10 
ATR:0.02 
Week High:0.790.0%
Week Low:0.756.0%
Month High:1.0735.4%
Month Low:0.7038.1%
Year High:1.68112.7%
Year Low:0.6423.6%